TW200829255A - Use of oestradiol in combination with dienogest for the oral treatment of dysfunctional uterine bleeding in conjunction with oral contraception - Google Patents
Use of oestradiol in combination with dienogest for the oral treatment of dysfunctional uterine bleeding in conjunction with oral contraception Download PDFInfo
- Publication number
- TW200829255A TW200829255A TW096100872A TW96100872A TW200829255A TW 200829255 A TW200829255 A TW 200829255A TW 096100872 A TW096100872 A TW 096100872A TW 96100872 A TW96100872 A TW 96100872A TW 200829255 A TW200829255 A TW 200829255A
- Authority
- TW
- Taiwan
- Prior art keywords
- combination
- stage
- estradiol
- dienogest
- daily
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Description
200829255 九、發明說明: 【發明所屬之技術領域】
段:2次醫藥學上可接受之安慰劑之每曰劑量。 該多階段藥物組合及醫藥學上可接受之安慰劑之每日劑 量的總數符合28天。 本發明係關於使用雌二醇與17α_氛基甲基⑽辛基雕 4,9-二稀-3,(地諾孕素)之組合以獲得用於口服治工療土里常 子呂=血結合口服避孕之具有總計28次每日劑量之多階段 組合製劑系統的用途;該雌二醇與地諾孕素之組人勺八· 第-階段’ 2次小於3 mg雌二醇之每曰劑量,·第二::, 由兩組不同之每曰劑量組成,其中第—組包含5:欠小於2 mg雌二醇與2 mg地諾孕素之組合之每日劑量^二組包含 17次小於2 mg雌二醇與3 mg&諾孕素之組合之每日劑量; 第二階段,2次小於1 mg雌二醇之每日劑量;及另一階 【先前技術】 異常子宮出血(DUB)係婦科醫學中一種常見的臨床問 題,且佔婦科醫學會診中高達33%之門診患者[參見JT.
Awwad,T.L· Toth及 I. Schiff: Abnormal uterine bleeding in the perimenopause,//?’· J· 38 (1993)第 261-269 頁]。 異常子宮出血之症狀如下: -月經週期持續7天以上, -月經週期間隔2 1天或更短時間發生,及 -排出80 ml或更多之異常劇烈月經出血。 咸僅應在排除諸如肌瘤、息肉及癌症之器官原因之後, 117772.doc 200829255 始可將其診斷為異常子宮出血。 DUB可發生㈣M卩期及非排㈣女性巾。其基本上由雕 激素刺激之子宮内膜增殖與助孕素促進之子宮内膜轉換之 間的不平衡引起。若異常子宮出血之症狀係歸因於過期不 排卵,則問題通常在於子宮内膜暴露於過量之雌激素增 殖。此不僅可導致異常出血,且亦導致子宮内膜增生[參 見 Speroff 等人,Clinical Gynec〇1〇gic End〇crin〇i〇gy (、 Infertility,第 6版,Lippinccm Williams & 粘旧叫 1999]。 子宮内膜增生係子宮内膜癌之風險因素。 在先前實驗中’用3x5 mg每曰劑量之炔諾酮 (norethisterone)或3x10 mg每曰劑量之醋酸甲羥孕酮作為 單一高劑量助孕素來治療異常子宮出血,在6名非排卵期 女性之情況下各藥物自週期之第丨2天至第25天投與丨4天, 且在10名排卵期女性之情況下各藥物自週期之第5天至第 25天投與20天[參見i.s· Fraser:如以·见z. J· 〇 办似%0厂,3〇,第4期(1990),第353-356頁]。兩組中出血 之持續時期均減少,但患者在此均未受到可靠避孕之保 護。 一評論文章闡明女性對不規則且劇烈之月經出血具有低 耐受性(參見 M· Hickey,J· Higham 及 I.S. Fraser: Progestogens versus oestrogens and progestogens f〇r irregular uterine bleeding associated with anovulation (Cochrane Review),於 The Cochrane Library,第 3 期, 2004 中 ’ John Wiley & Sons Ltd·, Chichester,England) 〇 該 117772.doc 200829255 等作者已描ϋ使用㈤孕素之基本原s以促進子纟内膜之轉 換,且因此產生更穩定之月經週期。然而,結論為該等治 療之功效並未在隨機研究中得到證實。 °
根據R. Steiner,尤其可用大劑量之助孕素、雌激素或兩 者之組合來治療異常子宮出血[參見R· steiner:糾吻 及⑽心ct Md.外似·,91,第 46 期(2000),第 1967_1974 頁]。該作者推薦以每曰6、5、4、3、3、3、3、3之遞減 劑量口服使用0.01 mg炔雌醇及2 mg醋酸炔諾酮歷時8天。 除此激素治療以外,Steiner主張用4x2錠劑每曰劑量之凝 血酸來治療急性出血。 A. Davis已藉由三階段投與炔雌醇(EE)及諾孕酯 (NGM),繼而投予無激素之安慰劑經三個28天之週期來治 療異常子宮出血[參見A· Davis,(9心加·幻;wco/·,96,第6 期(200 0),第913-920頁]。該療法為炔雌醇劑量保持恆定 為〇·〇35 mg歷時21天,而諾孕酯劑量在21天内逐漸增加(第 一個7天之0.1 80 mg至下一個七天之〇·2 15 mg,且隨後為最 後七天之0.250 mg),且此後為七天無激素之安慰劑過程。 在此安慰劑對照研究中,45%女性出現過量經血(子宮出 血 月經過多及月經次數過多(polymenorrhoea)),且約 5 5 A經血減少(月經次數過少(oligomenorrhoea))。此第二組 展示與安慰劑相比之最佳結果,其中誘發規則性出血消 退。月經次數過少並非為異常子宮出血之必然症狀,但已 知其需要治療。 在美國專利第6,797,282號之說明書中,通常揭示歷時三 117772.doc 200829255 個月之長期投予口 t手杲迥用於治療月經過多,月經過 多為一種異常子宮出血之類型。 【發明内容】 本^之目的在於提供—種治療異常子宮出血之方法, "I Ί出血1 ’預防異常子宮出血之復發,且同時提 供可靠且耐受性良好之口服避孕藥。 Γ 斤用術,吾異常子宮出血,,表示無器官原因之以下病 症之·月經週期持續7天以上、子宮出血間隔。天或更 短時:’或排出8〇ml或更多月經之劇烈出血。 本毛月之目的係藉由使用雌二醇與”心氰基甲基_17卜羥 二^ ’9 _烯_3_酮(地諾孕素)之組合以提供用以口服治療 異常子宮出血結合口服避孕之多階段組合製劑而達成。本 使用之雌一醇_地諾孕素組合包含第一階段,2次小於3 mg雌一醇、較佳2·25 mg雌二醇之每日劑量;第二階段, 兩組不同之每日劑量,其中第一組包含5次小於2叫雖二 酉予、較佳1.5 mg雌二醇與2 mg地諾孕素之組合之每日劑量 且第二組包含17次小於2 mg雌二醇、較佳l5 mg·二醇與 3 mg地諾孕素之組合之每日劑量丨第三階段,2次小於工 mg雌二醇、較佳〇·75 mg雌二醇之每日劑量;及另一階 段:2次醫藥學上可接受之安慰劑之每曰劑量。 該多階段藥物組合及醫藥學上可接受之安慰劑之每曰劑 量的總數符合28天。 忒療法至少採用一個週期,治療長度視患者之避孕需要 而定。 117772.doc 200829255 【實施方式】 所主張調配物之作用調查 對180名年‘在18‘5〇歲之間之女性進行隨機雙盲安慰劑 對照臨床研究,該笙‘ & = # i 茨寻女性已書面同意參與研究,呈現異常 子S出血之症狀,且已藉助於適當診斷方法(即陰道超音 掃描及血液激素含量測定)排除了器官原0。在該組中, 對〇名女丨生、、、6與根據所主張組合之戊酸雌二醇及地諾孕 素,而60名女性則接受安慰劑來代替。 。亥研九包含確定出血不規則性之嚴重程度的卯天試行階 丰又奴後為恰好六個月經週期之治療,且最後為跟蹤階 使用在整個研究期間女性所收集且上交至研究中心之衛 生巾及類似物,藉助於驗性血色素法定量測定出血強度。 由電子日σ己本中所記錄之日誌來判定出血之持續時間及非 出血間隔之長度。 實例 實例1 第卩白#又,2次2 ·9 mg雌二醇之每日劑量; 第二階段,兩組不同之每日劑量, 八弟"且包含$次1 ·9 mg雌二醇與2 mg地諾孕素之組 合之每日劑量,且 、、匕δ 1人1.9 mg雌一醇與3 mg地諾孕素之組合之 每曰劑量; 第一 P白#又,2次0.95 mg雌二醇之每曰劑量;及 117772.doc -10- 200829255 I3白奴,2次醫藥學上可接受之安慰劑之每曰 從而雜々 X得具有總計2 8次每日劑量之多階段組合製劑。 實例2 第階段,2次2·25 mg雌二醇之每日劑量; 第一階段,兩組不同之每日劑量, 其中第一組包含5次1.5 mg雌二醇與2 mg地諾孕素之組 合之每日劑量,且 第二組包含17次1.5 mg雌二醇與3 mg地諾孕素之組合之 每曰劑量; 第三階段,2次0·75 mg雌二醇之每曰劑量;及 另一 1¾段’ 2次醫藥學上可接受之安慰劑之每日劑量, 從而獲得具有總計2 8次每日劑量之多階段組合製劑。 117772.doc 11
Claims (1)
- 200829255 十、申請專利範圍: 一種使用雌二醇與17α-氰基甲基-17β-羥基雌-4,9_二烯-酮(地諾孕素(dienogest))之組合以獲得用於口服治療異常 子宮出血結合口服避孕之具有總計2 8次每日劑量之多階 段組合製劑的用途,該雌二醇與17α-氰基甲基_17(3-羥基 雌-4,9-二烯-3-酮(地諾孕素)之組合包含: 弟一階段,2次小於3 mg雖二醇之每日劑量; 第二階段,兩組不同之每曰劑量, 其中弟一組包含5次小於2 mg雌二醇與2 mg地諸孕 素之組合之每日劑量,且 第二組包含17次小於2 mg雌二醇與3 mg地諾孕素之 組合之每日劑量; 第二階段,2次小於1 mg雌二醇之每日劑量;及 另一階段:2次醫藥學上可接受之安慰劑之每曰劑 量° 2. U 一種使用雌二醇與17α_氰基曱基_170_羥基雌_4,9_二稀_3_ 酮(地諾孕素(dienogest))之組合以獲得用於口服治療異常 子宮出血結合口服避孕之具有總計28次每日劑量之多階 段組合製劑的用途,該雌二醇與17α-氰基甲基_170_羥基 雌-4,9_ 一烯酮(地諾孕素)之組合包含:第一階段,2 次2.25 mg雌二醇之每日劑量;第二階段,兩組不同之每 曰劑里’其中第一組包含5次15 mg雌二醇與2 mg地諾孕 素之組合之每日劑量且第二組包含17次1.5 mg雌二醇與3 mg地諾孕素之組合之每日劑量;第三階段,2次〇.75 mg 117772.doc 200829255 雌二醇之每日劑量;及另一階段:2次醫藥學上可接受 之安慰劑之每日劑量。 117772.doc -2- 200829255 七、指定代表圖: (一) 本案指定代表圖為:(無) (二) 本代表圖之元件符號簡單說明: 八、本案若有化學式時,請揭示最能顯示發明特徵的化學式: (無) f' 117772.doc
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05022324A EP1787649B1 (de) | 2005-10-13 | 2005-10-13 | Verwendung von Estradiolvalerat in Kombination mit Dienogest zur oralen Therapie der dysfunktionellen uterinen Blutung in Einheit mit einer oralen Kontrazeption |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200829255A true TW200829255A (en) | 2008-07-16 |
Family
ID=35811580
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW095137564A TWI328453B (en) | 2005-10-13 | 2006-10-12 | Use of estradiol valerate in combination with dienogest in order to obtain a multi-stage combined preparation with a total of 28 daily doses for the treatment of dysfunctional uterine bleeding in conjunction with oral contraception |
TW096100872A TW200829255A (en) | 2005-10-13 | 2007-01-09 | Use of oestradiol in combination with dienogest for the oral treatment of dysfunctional uterine bleeding in conjunction with oral contraception |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW095137564A TWI328453B (en) | 2005-10-13 | 2006-10-12 | Use of estradiol valerate in combination with dienogest in order to obtain a multi-stage combined preparation with a total of 28 daily doses for the treatment of dysfunctional uterine bleeding in conjunction with oral contraception |
Country Status (22)
Country | Link |
---|---|
EP (2) | EP1787649B1 (zh) |
JP (2) | JP5735200B2 (zh) |
KR (2) | KR20080065651A (zh) |
CN (1) | CN101312733A (zh) |
AR (1) | AR056694A1 (zh) |
AT (2) | ATE424828T1 (zh) |
CA (1) | CA2623024C (zh) |
CL (1) | CL2011000283A1 (zh) |
CY (2) | CY1110321T1 (zh) |
DE (2) | DE502005006837D1 (zh) |
DK (2) | DK1787649T3 (zh) |
DO (1) | DOP2006000221A (zh) |
ES (2) | ES2322479T3 (zh) |
HR (1) | HRP20090256T1 (zh) |
ME (1) | ME01056B (zh) |
PE (2) | PE20100090A1 (zh) |
PL (2) | PL1787649T3 (zh) |
PT (2) | PT1787649E (zh) |
SI (2) | SI1787649T1 (zh) |
TW (2) | TWI328453B (zh) |
UY (1) | UY29861A1 (zh) |
WO (1) | WO2007042296A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004019743B4 (de) | 2004-04-20 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens |
ES2322479T3 (es) * | 2005-10-13 | 2009-06-22 | Bayer Schering Pharma Aktiengesellschaft | Utilizacion de valerato de estradiol en combinacion con dienogest para la terapia por via oral de la hemorragia uterina disfuncional, en union con una contracepcion oral. |
US8153616B2 (en) | 2005-10-17 | 2012-04-10 | Bayer Pharma Aktiengesellschaft | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
EP1930010A1 (de) | 2006-10-20 | 2008-06-11 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4429374C1 (de) * | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
DE19540253C2 (de) * | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
AU4043597A (en) * | 1996-07-26 | 1998-02-20 | American Home Products Corporation | Biphasic contraceptive method and kit comprising a combination of a progestin and estrogen |
US6251956B1 (en) | 1998-08-20 | 2001-06-26 | Ortho Pharmaceutical Corporation | Combination progestin oral contraceptive regimen |
EP1462106A1 (en) * | 2003-03-28 | 2004-09-29 | Pantarhei Bioscience B.V. | Pharmaceutical compositions and kits comprising 17-beta-estradiol and a progesteron for the treatment of gynecological disorders |
DE102004019743B4 (de) * | 2004-04-20 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens |
ES2322479T3 (es) * | 2005-10-13 | 2009-06-22 | Bayer Schering Pharma Aktiengesellschaft | Utilizacion de valerato de estradiol en combinacion con dienogest para la terapia por via oral de la hemorragia uterina disfuncional, en union con una contracepcion oral. |
-
2005
- 2005-10-13 ES ES05022324T patent/ES2322479T3/es active Active
- 2005-10-13 SI SI200530672T patent/SI1787649T1/sl unknown
- 2005-10-13 PT PT05022324T patent/PT1787649E/pt unknown
- 2005-10-13 DK DK05022324T patent/DK1787649T3/da active
- 2005-10-13 DE DE502005006837T patent/DE502005006837D1/de active Active
- 2005-10-13 EP EP05022324A patent/EP1787649B1/de not_active Revoked
- 2005-10-13 PL PL05022324T patent/PL1787649T3/pl unknown
- 2005-10-13 AT AT05022324T patent/ATE424828T1/de active
- 2005-10-13 ME MEP-2009-171A patent/ME01056B/me unknown
-
2006
- 2006-10-12 PL PL06806225T patent/PL1933843T3/pl unknown
- 2006-10-12 CA CA2623024A patent/CA2623024C/en active Active
- 2006-10-12 JP JP2008534936A patent/JP5735200B2/ja active Active
- 2006-10-12 WO PCT/EP2006/009867 patent/WO2007042296A1/de active Application Filing
- 2006-10-12 EP EP06806225A patent/EP1933843B1/de active Active
- 2006-10-12 CN CNA2006800381810A patent/CN101312733A/zh active Pending
- 2006-10-12 AT AT06806225T patent/ATE497387T1/de active
- 2006-10-12 PE PE2009001256A patent/PE20100090A1/es not_active Application Discontinuation
- 2006-10-12 PE PE2006001241A patent/PE20070555A1/es not_active Application Discontinuation
- 2006-10-12 KR KR1020087011203A patent/KR20080065651A/ko not_active Application Discontinuation
- 2006-10-12 DK DK06806225.6T patent/DK1933843T3/da active
- 2006-10-12 TW TW095137564A patent/TWI328453B/zh active
- 2006-10-12 ES ES06806225T patent/ES2360302T3/es active Active
- 2006-10-12 KR KR1020107014574A patent/KR101218872B1/ko active IP Right Grant
- 2006-10-12 PT PT06806225T patent/PT1933843E/pt unknown
- 2006-10-12 SI SI200630991T patent/SI1933843T1/sl unknown
- 2006-10-12 DE DE502006008853T patent/DE502006008853D1/de active Active
- 2006-10-13 AR ARP060104489A patent/AR056694A1/es not_active Application Discontinuation
- 2006-10-13 UY UY29861A patent/UY29861A1/es not_active Application Discontinuation
- 2006-10-13 DO DO2006000221A patent/DOP2006000221A/es unknown
-
2007
- 2007-01-09 TW TW096100872A patent/TW200829255A/zh unknown
-
2009
- 2009-05-05 HR HR20090256T patent/HRP20090256T1/xx unknown
- 2009-06-11 CY CY20091100621T patent/CY1110321T1/el unknown
-
2011
- 2011-02-10 CL CL2011000283A patent/CL2011000283A1/es unknown
- 2011-05-02 CY CY20111100422T patent/CY1111406T1/el unknown
-
2012
- 2012-11-19 JP JP2012253067A patent/JP2013047269A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7177313B2 (ja) | 避妊用組成物および避妊方法 | |
KR100669165B1 (ko) | 3 단계 경구 피임제 | |
Mohamed et al. | Combined contraceptive ring versus combined oral contraceptive (30-μg ethinylestradiol and 3-mg drospirenone) | |
US20070238713A1 (en) | Methods for prevention and treatment of conditions arising from local estrogen deficiency | |
KR20150058555A (ko) | 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리 | |
TW200944211A (en) | Method for treating uterine fibroids | |
LaGuardia et al. | Suppression of estrogen-withdrawal headache with extended transdermal contraception | |
Depypere et al. | A 60-month non-comparative study on bleeding profiles with the levonorgestrel intrauterine system from the late transition period to estrogen supplemented menopause | |
Bygdeman et al. | Options for early therapeutic abortion: a comparative review | |
TW200829255A (en) | Use of oestradiol in combination with dienogest for the oral treatment of dysfunctional uterine bleeding in conjunction with oral contraception | |
PL192979B1 (pl) | Zastosowanie estrogenowo-progesteronowej hormonalnej kompozycji | |
US8153616B2 (en) | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same | |
US20060183725A1 (en) | Pharmaceutical preparation for oral contraception | |
WO2021229559A2 (en) | Use of combined oral contraceptives containing nomegestrol acetate and estradiol | |
JP2010520159A (ja) | 子宮内膜症の緩和のための医薬調製物 | |
Elia et al. | Efficacy and tolerability of a low-dose of Oesclim®(25 mcg daily) in the management of symptomatic menopausal women: a French open-label study | |
US20070088011A1 (en) | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same | |
TW200946542A (en) | New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen | |
PT1937274E (pt) | Utilização de valerato de estradiol em combinação com dienogest para a terapia oral da hemorragia uterina disfuncional em conjunto com uma contracepção oral | |
CN108853007A (zh) | 一种治疗功能性子宫出血的凝胶制剂及其用途 | |
KR20030043797A (ko) | 호르몬 조성물 | |
Lee et al. | Scenario 4: Choice of hormone replacement therapy (HRT) | |
Genazzani et al. | 2004 OUTLOOK ON HORMONE REPLACEMENT THERAPY | |
MXPA06006031A (en) | Extended use combination comprising estrogens and progestins | |
TW200942242A (en) | New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen |